Can bone marrow‐derived mesenchymal stem cells change liver volume?: A case report. Issue 2 (17th December 2020)

• Record Type: Journal Article
• Authors: Kim, Kwangmin; Shin, In Sik; Bang, Hui‐Jae; An, Sanghyun; Ha, Gaesung; Kim, Hyun Soo; Bae, Keum Seok
• Is Part Of: JGH open. Volume 5:Issue 2(2021)
• Page Start: 320
• Page End: 323
• Publication Date: 2020-12-17
• Subjects: computed tomography -- liver cirrhosis -- liver volume -- mesenchymal stem cell
• DOI: 10.1002/jgh3.12466
• Languages: English
• ISSNs: 2397-9070

Abstract

Abstract: Several studies have described the effectiveness of mesenchymal stem cell (MSC) transplantation in patients with liver cirrhosis (LC). However, in the majority, biochemical tests, clinical features, and pathologic results were used rather than radiologic tests to compare treatment outcomes. A 57‐year‐old male visited a stem cell clinic with a diagnosis of LC attributed to hepatitis B virus. This patient took tenofovir and diuretics at the initial presentation and was administered bone marrow‐derived MSCs twice via hepatic intra‐arterial infusion. Subsequently, the patient's clinical symptoms and biochemical tests (aspartate aminotransferase, alanine aminotransferase, albumin, total bilirubin, international normalized ratio, creatinine, alpha‐fetoprotein) improved. Computed tomography findings showed loss of ascites, reduced nodularity, and especially increased liver volume, which suggested that MSCs have meaningful effects on liver volume, as well as improving liver function. Abstract : Indeed, many studies have reported the effectiveness of mesenchymal stem cell (MSC) transplantation in patients with liver cirrhosis (LC). However, in most of these studies, biochemical tests, clinical features, and pathologic results were used rather than radiologic tests to compare treatment outcomes. This case report demonstrates the effectiveness of MSC infusion based on computed tomography findings of an increase in liver volume in a patient with hepatitis B virus associated LC.